Details
Category: Volume 3 Issue 12 December 2015
Hits: 5401

Title: First Study to Compare the Effect of Moxonidine and Clonidine on Blood Pressure and Kidney Function in Patients with Chronic Kidney Disease

Authors: Vikash Khandelia, Badrilal Patidar, Umashankar Shukla, Vandana Meena

 DOI:  http://dx.doi.org/10.18535/jmscr/v3i12.09

Abstract

Hypertension is 2-3 times more prevalent in CKD as compared to the general population. Enhancement of renal sympathetic nerve activity during renal ischemia and norepinephrine overflow from the kidney after reperfusion are responsible for the development of ischemic acute kidney injury. Angiotensin receptor antagonists and Angiotensin -converting enzyme inhibitors are unable to normalize sympathetic hyperactivity in patients with hypertensive chronic renal failure in spite of lowering blood pressure. Moxonidine is considered to differ from the other centrally acting sympatholytic drugs. Fifty patients of CKD were enrolled in the moxonidine group and forty nine patients were enrolled in the clonidine group in this open label randomized study. A significant reduction in SBP and DBP was observed in both the treatment groups as compared to baseline. A significant difference between treatment groups was observed. Moxonidine caused a significantly greater reduction of SBP and DBP as compared to clonidine at the end of 3 months. Serum Creatinine was significantly lower after treatment in the moxonidine group as compared to the clonidine group. eGFR after 3 months of treatment was significantly higher in the  moxonidine group. Moxonidine can be a preferred sympatho-inhibitory drug in renal failure patients.

References

  1. Tyson CC1, Coffman TM.In the Wake of Systolic Blood Pressure Intervention Trial: New Targets for Improving Hyperten-sion Management in Chronic Kidney Disease? 2017;135(4):287-290.
  2. Jagdish S. Hiremath,1Vijay M. Katekhaye,2 Vijay S. Chamle,3 Rishi M. Jain,4 and Amit I. Bhargava5Current Practice of Hypertension in India: Focus on Blood Pressure GoalsJ Clin Diagn Res. 2016 Dec; 10(12): OC25–OC28.
  3. Neumann J1, Ligtenberg G, Oey L, Koo-mans HA, Blankestijn PJ.Moxonidine nor-malizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004 Nov;15(11):2902
  4. Chan CK, Burke SL, Zhu H, Piletz JE, Head GA.Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine.2005;132(4):991-1007.
  5. Edwards LP1, Brown-Bryan TA, McLean L, Ernsberger P.Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther. 2012 Aug;30(4):199-208.
  6. Ebinç H1,Ozkurt ZN, Ebinç FA, Ucardag D, Caglayan O, Yilmaz M.Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women. J Int Med Res. 2008 Jan-Feb;36(1):80-7.
  7. Koomans HA, Blankestijn PJ, Joles JA: Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 15: 524–537, 2004
  8. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treat-ment. Kidney Int 65: 1568–1576, 2004
  9. Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant 19: 1354–1357, 2004
  10. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circul-ation 105:1354–1359, 2002
  11. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321–1328, 1999
  12. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14: 425–430, 2003
  13. Prichard BN, Graham BR, Owens CW: Moxonidine: A new antiadrenergic antihy-pertensive agent. J Hypertens 17 Suppl 3: S41–S54, 1999
  14. Ernsberger P: Pharmacology of moxon-idine: An I1-imidazoline receptor agon-ist. J Cardiovasc Pharmacol 35: S27–S41, 2000.
  15. Kirch W, Hutt HJ, Planitz V: The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 15: 245–253, 1988.
  16. Hausberg, Martina,d,*; Tokmak, Farukb,*; Pavenstädt, Hermanna; Krämer, Bernhard Kb; Rump, Lars Christianb,cEffects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. Journal of Hypertension: September 2010 - Volume 28 - Issue 9 - p 1920–1927.

Corresponding Author

Vikash Khandelia

Assistant Professor Department of Nephrology,

Government Medical College Kota, Rajasthan, India